NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
$286.22 +$14.45 (+5.32%) 1D Market openKey Metrics
$36.28B
Market cap
115.65×
P/E · TTM
$3.71B
Revenue · TTM
$313.75M
Net income
EPS · TTM
$2.51
Dividend yield
—
Free cash flow
$465.38M
Beta · 1Y
0.49
EBITDA · TTM
$378.81M
Gross margin
—
Snapshot
Market cap$36.28B
Enterprise value—
Shares outstanding133.5M
52-wk range$262.21 – $495.55
Avg volume · 20D865.7K
Net cash
—
Book value / share$6.32
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Alnylam Pharmaceuticals, Inc.
IPO dateMay 28, 2004
Employees2500
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E115.65
P/S9.77
P/FCF77.97
EV/EBITDA—
EV/Sales—
Graham №$18.90
Profitability
Gross
—
Operating
8.7%
Net
8.4%
FCF
12.5%
ROE / ROIC
73.3% · -14.8%
Financial Health
Current ratio2.76
Quick ratio2.71
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$2.58B
Cash Flow · TTM
Operating CF
$524.08M
Capex
−$58.70M
Free cash flow
$465.38M
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
5 / 9
Middling fundamentals · 5 of 9 signals passing
Altman Z-Score
4.9
Safe zone (> 2.99) · bankruptcy risk negligible
Graham Number vs Price
$18.90 vs $278.40
Trades 14.7× above classic defensive value — priced for growth
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings